| Identification | Back Directory | [Name]
Acetylspiramycin | [CAS]
24916-51-6 | [Synonyms]
C12891
spiramycin2
spiramycinb
foromacidinb
Acetyl helix
spiramycin ii
foromacidineb
ACETYLSPIRAMYCIN
Spiramycin II (6CI)
Spiramycin B (7CI, 8CI)
Acetyl SpiraMycin (Contains Monoacetyl, Diacetyl and Triacetyl)
9-o-(5-(dimethylamino)tetrahydro-6-methyl-2h-pyran-2-yl)-leucomycin3-ac
9-O-[(2R,5S,6R)-5-Dimethylaminotetrahydro-6-methyl-2H-pyran-2-yl]leucomycin V 3-acetate
9-O-[(2R,5S,6R)-5-(Dimethylamino)tetrahydro-6-methyl-2H-pyran-2-yl]-3-acetate-leucomycin V
Leucomycin V, 9-O-[(2R,5S,6R)-5-(dimethylamino)tetrahydro-6-methyl-2H-pyran-2-yl]-, 3-acetate
Leucomycin V, 9-O-[5-(dimethylamino)tetrahydro-6-methyl-2H-pyran-2-yl]-, 3-acetate, [9(2R,5S,6R)]- | [EINECS(EC#)]
1312995-182-4 | [Molecular Formula]
C45H76N2O15 | [MDL Number]
MFCD01684079 | [MOL File]
24916-51-6.mol | [Molecular Weight]
885.09 |
| Chemical Properties | Back Directory | [Appearance]
Crystalline Solid | [Melting point ]
130-1330C | [alpha ]
D20 -86° | [Boiling point ]
916.7±65.0 °C(Predicted) | [density ]
1.21±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
DMSO (Slightly, Sonicated), Methanol (Very Slightly, Heated) | [form ]
Solid | [pka]
13.06±0.70(Predicted) | [color ]
White to Light Yellow | [InChIKey]
TXVWWVGEGBCUMX-HOUNXPESSA-N | [CAS DataBase Reference]
24916-51-6 |
| Hazard Information | Back Directory | [Chemical Properties]
Crystalline Solid | [Uses]
Antibiotic substance classified in the erythromycin-carbomycin group | [Definition]
ChEBI: A macrolide antibiotic produced by various Streptomyces species. | [in vivo]
Acetylspiramycin (25-200 mg/kg/day; Oral gavage (p.o.); 7 days) can significantly enhance the lymphocyte proliferation response of CBA/H mice to PHA, and reduce the activity of lymphokine in a dose-dependent manner[3].
Acetylspiramycin (50-200 mg/kg/day; Oral gavage (p.o.); 14 days) in CBA/H mouse models can increase the efficiency of phagocytosis in mice[4].
| Animal Model: | CBA/H mice | | Dosage: | 25-200 mg/kg/day | | Administration: | Oral gavage (p.o.), 7 days | | Result: | Decreased lymphokine activity in a dose-dependent manner |
| Animal Model: | CBA/H mice[4] | | Dosage: | 50-200 mg/kg/day | | Administration: | Oral gavage (p.o.), 14 days | | Result: | Increased the efficiency of phagocytosis in mice. |
| [IC 50]
Macrolide | [storage]
Store at -20°C |
|
|